

Pneumothorax with Pneumomediastinum and Extensive Subcutaneous Emphysema Related to Covid-19 Infection

Ekkehard Pietsch*

Orthopaedic and General Surgeon, Department of Orthopaedic and Trauma, The-Expert-Witness.de, Hamburg, Germany

*Corresponding Author: Ekkehard Pietsch, Orthopaedic and General Surgeon, Department of Orthopaedic and Trauma, The-Expert-Witness.de, Hamburg, Germany.

Received: March 08, 2021; Published: March 26, 2021

Abstract

Spontaneous pneumothorax, which is not related to positive pressure ventilation, are currently seen in patients with COVID-19 pneumonia. It has been suggested that the possible pathophysiological mechanism is due to a diffuse alveolar injury leading to alveolar rupture and air leakage. We present a case of COVID-19 pneumonia, which was complicated by pneumothorax, pneumomediastinum and extensive emphysema on admission. The patient had no identifiable risk factors. He is a non-smoker without lung comorbidities or reported coughing. The patient underwent medical treatment for his COVID-19 infection with drainage but did not require invasive or non-invasive ventilation. He could be discharged home in stable condition. A review of the available literature revealed 15 other cases of spontaneous pneumomediastinum associated with COVID-19 pneumonia.

Keywords: Covid-19 Infection; Corona Infection; Covid-19 Related Pneumonia; Covid-19 Related Pneumothorax; Covid-19 Related Subcutaneous Emphysema; Covid-19 Related Pneumomediastinum

Introduction

By the end of 2019, the first notified cases of pneumonia with unknown aetiology were reported in Wuhan, China [1,2]. The clinical picture reminded of an acute respiratory distress syndrome (ARDS), which was identified as being a novel coronavirus [3]. It resulted in a worldwide spread of the virus and was declared a worldwide pandemic on 11 March 2020. To date, more than 127 Mio cases of infections have been noted with 2.8 Mio fatalities [4]. Over time, physicians have learned that the virus is of intrusive nature and does not only affect lungs but the entire organ systems creating various complications.

This case study presents a rare case of SARS-CoV-2 with pneumonia that was complicated by spontaneous pneumothorax, pneumomediastinum and extensive subcutaneous emphysema without the use of any pressure ventilation. Treatment could be managed conservatively although the patient was at a high risk due to his underlying complications.

Case Report

A 62-year-old male patient with a 6-day history of fever (maximum body temperature was about 39°C) and a rapidly progressing dyspnea since the day before A&E presentation was admitted to the hospital. On admission, he presented with extensive subcutaneous emphysema that involved the entire body from the head down to the thighs. Oxygen saturation under 2 l oxygen was 89%. He was tested positive for Covid 19 infection by corona virus nucleic acid testing by RT-PCR.

Initial X-rays revealed a pneumothorax on the left with additional bilateral opacities in the upper and middle lobes. CT images showed multiple bilateral ground glass opacities, which were consistent with COVID-19 changes.

Citation: Ekkehard Pietsch. "Pneumothorax with Pneumomediastinum and Extensive Subcutaneous Emphysema Related to Covid-19 Infection". *EC Pulmonology and Respiratory Medicine* 10.4 (2021): 34-37.

Pneumothorax with Pneumomediastinum and Extensive Subcutaneous Emphysema Related to Covid-19 Infection

His complete blood count revealed leukocytes 7.20 x 109 /L (3.5 - 9.5 x 109/L), thrombopenia 118 x 109/L (125 to 350 x 109/L), lymphopenia 0.61 x 109/L (1.1 to 3.2 x 109/L and neutrophils 5.55 x 109/L (1.8 to 6.3 x 109/L). Serum procalcitonin was 0.6 ng/mL (< 0.05 ng/mL), LDH 598 U/l (< 250 U/l.) with C-reactive protein 112 mg/L (< 3 mg/L). Blood gas analysis showed pH 7.46 (7.35 to 7.45), oxygen partial pressure of 104 mmHg (83 to 108 mmHg) and carbon dioxide 45 mmHg (33 to 46 mmHg).



Figure 1: Extensive subcutaneous emphysema.



Figure 2: CT chest: Pneumothorax of the left lung with pneumomediastinum and extensive subcutaneous emphysema.

Citation: Ekkehard Pietsch. "Pneumothorax with Pneumomediastinum and Extensive Subcutaneous Emphysema Related to Covid-19 Infection". *EC Pulmonology and Respiratory Medicine* 10.4 (2021): 34-37.

35

The patient received a chest drain and was put on 20 mmHg suction, 2l oxygen, lopinavir/ritonavir as well as antibiotics (initially cefoperazone-sulbactam followed by imipenem- cilastatin). Besides, he was also treated with steroid therapy (methylprednisolone 40 mg daily iv).

With high-flow nasal cannula and oxygen, intravenous steroid therapy over three days (methylprednisolone 20 mg/d) followed by oral Prednisone tablets for further four days (10 mg/d) for suspected cytokine storm. X-ray follow-ups could demonstrate full expansion of the collapsed lung. Clinical symptoms gradually improved over a period of 6 days. Pneumothorax and subcutaneous emphysema were absorbed completely. Ten days after admission, the patient had no more evidence of Corona virus in 2 consecutive RT-PCR tests.

Discussion

Spontaneous rupture of a subpleural bulla is the most common cause of primary spontaneous pneumothorax [5]. Contributing risk factors for the development of spontaneous pneumothorax have been identified by Wang [6] as tobacco smoking, male sex, age, low body mass index, thin stature, strenuous exercise, prolonged cough, and lung diseases, i.e. chronic obstructive pulmonary disease (COLD).

Spontaneous pneumomediastinum and pneumothorax, which are not related to positive pressure ventilation, have been reported as a rare and unusual complication in patients with severe COVID-19 pneumonia. It must be assumed that the pathophysiological mechanism results from a diffuse alveolar injury leading to alveolar rupture and air leak [7]. Subcutaneous emphysema usually occurs when air leaks into tissues under the skin, which is common after pneumothorax. Dyspnea is non-specific and a common symptom for severe COVID-19 pneumonia, pneumothorax and pneumomediastinum. This may not occur in the acute phase of infection but also as late sequelae in the course of recovery weeks after infection [8].

During the pandemic, typical features of COVID-19 have been identified. CT scans in the early phase can reveal bilateral multilobar and reticular ground-glass opacification that are localised in the periphery or the posterior aspects of the lungs with middle/lower predominance [9]. About one percent of COVID-19 patients develop a pneumothorax [10]. And finally, spontaneous pneumomediastinum, usually a rare condition, refers to alveolar rupture due to an increase in intrathoracic pressure, followed by air dissection through the bronchovascular sheath into the mediastinum.

Our case had spontaneous pneumothorax, additional pneumomediastinum and subcutaneous emphysema at the same time, which contributes to a rare clinical complication as a result of Covid-19 pneumonia.

Conclusion

This case is a reminder that acute clinical deterioration with oxygen desaturation in a COVID-19 patient with pneumonia can indicate pneumothorax or pneumomediastinum. The best management of such cases is yet still unknown. In this case, we treated with steroid therapy because we suspected a possible cytokine storm. The patient recovered well and without further surgical interventions. It is of note that the significance of the timing and the efficacy of steroid therapy in COVID-19 patients with severe pneumonia also remains unknown.

Acknowledgements

No financial support was received for this study. Picture with patient's permission.

Citation: Ekkehard Pietsch. "Pneumothorax with Pneumomediastinum and Extensive Subcutaneous Emphysema Related to Covid-19 Infection". *EC Pulmonology and Respiratory Medicine* 10.4 (2021): 34-37.

36

Pneumothorax with Pneumomediastinum and Extensive Subcutaneous Emphysema Related to Covid-19 Infection

Bibliography

- 1. Sun J., *et al.* "COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives". *Trends in Molecular Medicine* 26.5 (2020): 483–495.
- 2. "WHO Points To Wildlife Farms In Southern China As Likely Source Of Pandemic". NPR. 15 March 2021
- 3. Adhanom, Tedros. "WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020". World Health Organization (WHO).
- 4. https://www.worldometers.info/coronavirus/
- 5. Light RW. "Management of spontaneous pneumothorax". The American Review of Respiratory Disease 148 (1993): 245-248.
- 6. Wang W., *et al.* "COVID-19 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema". *Journal of Travel Medicine* 27.5 (2020): 062.
- 7. Elhakim TS., *et al.* "Spontaneous pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19 pneumonia: a rare case and literature review". *BMJ Case Reports* 13.12 (2020): e239489.
- 8. Hollingshead C and Hanrahan J. "Spontaneous Pneumothorax Following COVID-19 Pneumonia". ID Cases 21 (2020): e00868.
- 9. Vancheri SG., *et al.* "Radiographic findings in 240 patients with COVID-19 pneumonia: time-dependence after the onset of symptoms". *European Radiology* (2020): 1-9.
- Chen N., et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet 395.10223 (2020): 507-513.

Volume 10 Issue 4 March 2021 All rights reserved by Robert S Fitzgerald., *et al.*